Integra Lifesciences Holdings Corp  

(Public, NASDAQ:IART)   Watch this stock  
Find more results for IART
+0.01 (0.02%)
Nov 21 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 47.05 - 48.57
52 week 42.50 - 51.76
Open 48.11
Vol / Avg. 119,675.00/178,031.00
Mkt cap 1.56B
P/E 51.79
Div/yield     -
EPS 0.92
Shares 32.79M
Beta 0.93
Inst. own 80%
Dec 10, 2014
Integra LifeSciences Holdings Corp at Oppenheimer Healthcare Conference - 2:45PM EST - Add to calendar
Dec 2, 2014
Integra LifeSciences Holdings Corp at Piper Jaffray Healthcare Conference - 9:30AM EST - Add to calendar
Nov 13, 2014
Integra LifeSciences Holdings Corp Investor Meeting at North American Spine Society
Nov 3, 2014
Q3 2014 Integra LifeSciences Holdings Corp Earnings Call - Webcast
Nov 3, 2014
Q3 2014 Integra LifeSciences Holdings Corp Earnings Release
Sep 9, 2014
Integra LifeSciences Holdings Corp at Morgan Stanley Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin 4.27% -2.03%
Operating margin 7.72% -0.44%
EBITD margin - 10.78%
Return on average assets 2.53% -1.44%
Return on average equity 5.72% -2.87%
Employees 3,300 -
CDP Score - -


311 Enterprise Drive
United States - Map
+1-609-2750500 (Phone)
+1-609-2755363 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Integra LifeSciences Holdings Corporation (Integra) is an integrated medical technology company. Integra offers solutions in orthopedic extremity surgery, neurosurgery, spine surgery, and reconstructive and general surgery. It has developed numerous product lines for applications ranging from burn and deep tissue wounds to regeneration of dura mater in the brain and repair of nerve and tendon. It operates in five business segments: U.S. Neurosurgery, U.S. Extremities, U.S. Instruments, U.S. Spine and Other, and International. The International segment sells similar products to Europe, Middle East and Africa, and Central/South America, Asia-Pacific and Canada. On April 30, 2013, it released its Hollywood VI intervertebral body fusion device (IBD) system. In January 2014, Integra LifeSciences Holdings Corp completed the acquisition of DuraSeal product lines from Covidien. In January 2014, Covidien PLC completed the sale of its Confluent Surgical product line to the Company.

Officers and directors

Stuart M. Essig Chairman of the Board
Age: 52
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Peter J. Arduini President, Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Glenn G. Coleman Chief Financial Officer, Principal Accounting Officer, Corporate Vice President
Age: 46
Bio & Compensation  - Reuters
Padma Thiruvengadam Chief Human Resources Officer, Corporate Vice President
Age: 49
Bio & Compensation  - Reuters
Kenneth E. Burhop Ph.D. Chief Scientific Officer, Corporate Vice President
Bio & Compensation  - Reuters
Judith E. O'Grady Corporate Vice President - Global Regulatory Affairs, Corporate Compliance Officer
Age: 63
Bio & Compensation  - Reuters
John Mooradian Corporate Vice President - Global Operations and Supply Chain
Age: 58
Bio & Compensation  - Reuters
Richard D. Gorelick Corporate Vice President, General Counsel, Administration, Secretary
Age: 53
Bio & Compensation  - Reuters
Jerry E. Corbin Corporate Vice President, Corporate Controller
Age: 53
Bio & Compensation  - Reuters
Mark A. Augusti Corporate Vice President, President, Orthopedics and Tissue Technologies
Bio & Compensation  - Reuters